预防肝癌肝移植术后肿瘤复发的研究现状及进展  

Current status and progress of research on prevention of tumor recurrenceeafterliver transplantation for hepatocellular carcinoma

作　　者：俞祺健 杨喆 郑树森 Yu Qijian;Yang Zhe;Zheng Shusen(The Clinical Medical College,Zhejiang Chinese Medical University,Hangzhou 310057,China;Department CP eliularcarcinoma rtertg Drtusen TheSecond of Hepatobiliary and Pancreatic Surgery,Shulan(Hangzhou)Hospital Afiliated to Zhejiang Shuren University Shulan International Medical College,Hangzhou 310022,China)

机构地区：[1]浙江中医药大学第二临床医学院,杭州310057 [2]浙江树人学院树兰国际医学院附属树兰(杭州)医院肝胆胰外科,310022

出　　处：《中华移植杂志（电子版）》2023年第3期171-179,共9页Chinese Journal of Transplantation(Electronic Edition)

基　　金：浙江省自然科学基金(Y21H160259);济南微生态生物医学省实验室科研项目(JNL-2022016B)

摘　　要：肝移植是根治性治疗肝细胞肝癌(HCC)的重要手段之一。随着全世界范围内HCC发病率的持续上升,以HCC为主要指征的等待肝移植患者数量也在不断增加。然而,肝移植后肿瘤复发问题仍然不可避免,并且是导致受者死亡的主要原因之一。因此,提高HCC肝移植远期疗效的关键在于如何预防移植后肿瘤复发。本文综述HCC肝移植受者和供者选择、术前桥接和降期治疗、移植术中无瘤技术和缺血再灌注损伤、个体化免疫抑制方案以及术后辅助治疗和抗病毒治疗等方面的最新进展,为预防HCC肝移植后肿瘤复发的研究及临床实践提供参考。Liver transplantation is one of the most important tools for the radical treatment of hepatocellular carcinoma(HCC).As the incidence of HCC continues to rise worldwide,the number of patients awaiting transplantation with HCC as a primary indication is increasing.However,the recurrence after transplantation remains inevitable and is one of the leading causes of death after liver transplantation.Therefore,the key to improving the long-term outcome of liver transplantation for HCC is to prevent tumor recurrence after transplantation.This article reviews recent advances in HCC liver transplant recipient and donor selection,preoperative bridging and downstaging therapy,intraoperative tumor-free techniques and ischemia-reperfusion injury in transplantation,personalized immunosuppressive regimens,and postoperative adjuvant and antiviral therapy to provide a reference for research and clinical practice in the prevention of tumor recurrence after liver transplantation for HCC.

关 键 词：肝细胞肝癌 肝移植 预防 复发 

分 类 号：R735.7[医药卫生—肿瘤]